Company:  CNS PHARMACEUTICALS, INC. (CNSP)
Form Type:  3
Filing Date:  11/8/2019 
CIK:  0001729427 
Address:  2100 WEST LOOP SOUTH
SUITE 900
 
City, State, Zip:  HOUSTON, Texas 77027 
Telephone:  1-800-946-9185 X701 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.32  
Change: 
0.161 (3.87%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$67.88M
Trade CNSP now with 

© 2019  
Description of Business
On November 21, 2017, we entered into a Collaboration and Asset Purchase Agreement with Reata. Through this agreement, we purchased all of Reata's rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, we agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from our first commercial sale of Berubicin plus $10,000. Reata also agreed to use commercially reasonable efforts, at the Company's expense, to provide development assistance related to the product and/or product intellectual property. On December 28, 2017, we entered into an Amended and Restated Patent License Agreement with HPI. HPI is owned by Dr. Priebe whom controls a majority of our shares. Pursuant to this Agreement, we obtained a worldwide, exclusive license to the chemical compound commonly known as WP744.
Register and access this filing in:     
  FORM 3
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24.1